Johnson & Johnson (JNJ)
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
- Ticker
- JNJ
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $680.83B
- 52-week range
- $193.55 - $290.25
Valuation
- Share price
- $282.55 (close of Nov 16, 2026)
- P/E (TTM)
- 42.30x
- Price to book
- 8.35x
- Price to free cash flow
- 33.07x
- Enterprise value
- $708.26B
- Book value per share
- $33.84
Price performance
| Period | Change |
|---|---|
| 1 day | -1.12% |
| 5 days | +0.16% |
| 1 month | +10.56% |
| 3 months | +8.53% |
| 6 months | +24.63% |
| Year to date | +36.53% |
| 1 year | +44.21% |
| 3 years | +88.24% |
| 5 years | +73.70% |
| 10 years | +142.82% |
| All time | +23,083.59% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 0.79%
- Shares short
- 17.07M
- Days to cover
- 2.41
- Change since prior report
- +1.80%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed JNJ trades
Thomas Kean · Lloyd Doggett · Josh Gottheimer · Lisa McClain · Richard McCormick · Gilbert Ray Cisneros · Julie Johnson · Marjorie Taylor Greene · Jefferson Shreve · Alan Armstrong · Bruce Westerman · Jared Moskowitz
Super investors holding JNJ
Ken Griffin (Citadel) · Yacktman Asset Mgmt (Yacktman Asset Management LP) · Ray Dalio (Bridgewater Associates) · Mairs & Power (Mairs & Power Inc) · Tweedy Browne (Tweedy Browne Company LLC) · Prem Watsa (Fairfax Financial Holdings) · John Rogers (Ariel Investments LLC) · George Soros (Soros Fund Mgmt) · Robert Olstein (Olstein Capital Management) · Dodge & Cox (Dodge & Cox Funds) · David Katz (Matrix Asset Advisors Inc) · Thomas Russo (Gardner Russo & Quinn LLC)
Profitability and growth
- Return on equity
- 32.87%
- Return on invested capital
- 21.45%*
- Return on assets
- 13.46%
- Return on capital employed
- 23.13%*
- Gross margin
- 67.88%
- Net margin
- 28.46%
- EBITDA margin
- 43.59%
- Revenue growth
- 6.05%
- Net income growth
- 90.56%
- Free cash flow growth
- -0.73%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.02%
- Current ratio
- 1.02x
- Net debt to EBITDA
- 1.02x
Latest reported year
- Period end
- Dec 28, 2025
- Fiscal year
- 2025
- Revenue
- $94.19B
- Cost of revenue
- $30.26B
- Gross profit
- $63.94B
- EBITDA
- $41.05B
- Net income
- $26.80B
- Earnings per share
- $11.13
- Research and development
- $14.66B
- Interest expense
- $971.00M
- Shares outstanding
- 2.41B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-28 | $94.19B | $63.94B | $26.80B | $11.13 |
| 2024-12-29 | $88.82B | $61.35B | $14.07B | $5.84 |
| 2023-12-31 | $85.16B | $58.61B | $35.15B | $13.88 |
| 2023-01-01 | $79.99B | $55.39B | $17.94B | $6.83 |
| 2022-01-02 | $78.74B | $55.34B | $20.88B | $7.93 |
| 2021-01-03 | $82.58B | $54.16B | $14.71B | $5.59 |
| 2019-12-29 | $82.06B | $54.50B | $15.12B | $5.72 |
| 2018-12-30 | $81.58B | $54.49B | $15.30B | $5.70 |
| 2017-12-31 | $76.45B | $51.01B | $1.30B | $0.48 |
| 2017-01-01 | $71.89B | $50.10B | $16.54B | $6.04 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-28 | 67.88% | 28.46% | 32.87% | 21.45%* |
| 2024-12-29 | 69.07% | 15.84% | 19.68% | 13.71%* |
| 2023-12-31 | 68.82% | 41.28% | 51.11% | 14.37%* |
| 2023-01-01 | 69.25% | 22.43% | 23.36% | 14.30%* |
| 2022-01-02 | 70.28% | 26.52% | 28.20% | 16.53%* |
| 2021-01-03 | 65.58% | 17.82% | 23.25% | 14.97%* |
| 2019-12-29 | 66.42% | 18.42% | 25.42% | 17.51%* |
| 2018-12-30 | 66.79% | 18.75% | 25.60% | 18.07%* |
| 2017-12-31 | 66.72% | 1.70% | 2.16% | 9.82%* |
| 2017-01-01 | 69.69% | 23.01% | 23.49% | 17.70%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-28 | $19.71B | $39.44B |
| 2024-12-29 | $24.11B | $30.65B |
| 2023-12-31 | $21.86B | $25.88B |
| 2023-01-01 | $12.89B | $26.89B |
| 2022-01-02 | $14.49B | $29.98B |
| 2021-01-03 | $25.18B | $32.63B |
| 2019-12-29 | $19.29B | $26.49B |
| 2018-12-30 | $19.69B | $27.68B |
| 2017-12-31 | $18.30B | $30.68B |
| 2017-01-01 | $41.91B | $22.44B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-28 | $19.70B | $1.35B |
| 2024-12-29 | $19.84B | $1.18B |
| 2023-12-31 | $18.25B | $1.16B |
| 2023-01-01 | $17.18B | $1.14B |
| 2022-01-02 | $19.76B | $1.14B |
| 2021-01-03 | $20.19B | $1.00B |
| 2019-12-29 | $19.92B | $977.00M |
| 2018-12-30 | $18.53B | $978.00M |
| 2017-12-31 | $17.78B | $962.00M |
| 2017-01-01 | $15.54B | $878.00M |
Dividend history
- Most recent payment
- Aug 25, 2026
- Paid in the last twelve months
- $5.28
| Payment date | Dividend per share |
|---|---|
| 2026-08-25 | $1.34 |
| 2026-05-26 | $1.34 |
| 2026-02-24 | $1.30 |
| 2025-11-25 | $1.30 |
| 2025-08-26 | $1.30 |
| 2025-05-27 | $1.30 |
| 2025-02-18 | $1.24 |
| 2024-11-26 | $1.24 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-13 | Sep 2026 | $2.53 |
| 2026-07-15 | Jun 2026 | $2.84 |
| 2026-04-14 | Mar 2026 | $2.67 |
| 2026-01-21 | Dec 2025 | $2.43 |
| 2025-10-14 | Sep 2025 | $2.77 |
| 2025-07-16 | Jun 2025 | $2.66 |
| 2025-04-15 | Mar 2025 | $2.57 |
| 2025-01-22 | Dec 2024 | $2.00 |
Filings and sources
- Company website
- jnj.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
AbbVie Inc. (ABBV) · Eli Lilly & Co (LLY) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades